GSK PLC

GSK PLC’s bold pivot: new CEO, U.S. expansion, key divestments, and strategic partnerships reshape a pharma giant poised for higher‑yield growth.

GSK’s new China partnership and Japan orphan‑drug approval lift its vaccine and oncology prospects, driving a 3.7 % share jump and boosting investor confidence.

GSK’s 2025 annual report, CEO pay hike, new FDA‑approved Flovent generic, and genomic research updates show how the pharma giant is steering growth and competition in 2026.

GSK’s EU approval of Exdensur, a new stem‑cell partnership and a £2bn share‑buyback fuel a bullish outlook, boosting revenue, pipeline breadth and shareholder returns.

GSK PLC reports Q4 2025 earnings, $11.46 B revenue growth, $0.42 EPS, new CEO plans product‑centric strategy, shares up 5.2 %.

GSK’s dual‑track strategy: China approves Trelegy Ellipta for 50 million adults, while a $2.2 billion RAPT acquisition boosts its oncology ADC platform, positioning GSK for growth.

GSK partners with Flagship Pioneering to boost biotech R&D, meets new FDA flu‑vaccine warnings, and taps accelerated review pathways for faster drug launches.

GSK’s latest regulatory wins—Shingrix prefilled syringe, bepirovirsen Phase III success, and new approvals for Exdensur and Nucala—signal a broad, growth‑focused portfolio poised to boost vaccine efficiency, advance hepatitis B cures, and expand spe…

GSK’s new Exdensur asthma drug and price‑reduction pact highlight its clinical leadership and commitment to patient‑centric care, boosting investor confidence and positioning the firm for growth in emerging biotech markets.

GSK’s new U.S. drug‑price deal and sale of Human Genome Sciences to Samsung Biologics signal a focused shift toward pricing, supply‑chain resilience and R&D investment, boosting investor confidence and positioning the pharma leader for future growth.